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Yellow fever virus (YFV) is a reemerging problem despite the existence of an effective live-attenuated vaccine. The
induction of YFV-neutralizing antibodies undoubtedly contributes to vaccine efficacy, but T lymphocyte responses to YFV
likely play a role in long-term efficacy. We studied the T lymphocyte responses to YFV in four vaccinees. Proliferation and
cytolytic responses to YFV were demonstrated in all subjects. We isolated 13 YFV-specific CD8 CTL lines that recognized
epitopes on the E, NS1, NS2b, and NS3 proteins; eight CTL lines were HLA-B35-restricted. YFV-specific T cell responses were
detectable by IFN ELISPOT assays 14 days postvaccination, with T cell frequencies sustained for up to 19 months. To our
knowledge, this is the first report of human T lymphocyte responses following YFV vaccination. These results indicate that
the live 17D YFV vaccine induced CD8 T cell responses directed against at least four different HLA-B35-restricted YFV
epitopes. © 2002 Elsevier Science (USA)s; cytoINTRODUCTION
Yellow fever virus (YFV) is a member of the family
Flaviviridae, which includes at least 68 single-stranded
RNA viruses transmitted by mosquitoes or ticks. Other
members of this family include dengue, Japanese en-
cephalitis, West Nile, and hepatitis C viruses. Yellow
fever is once again emerging as an important infectious
disease in Africa, South America, and Central America.
According to the WHO, the 18,735 cases with 4522
deaths reported in the endemic areas of Central and
South America during the period of 1987–1991 were the
highest since 1948 (Robertson et al., 1996). YFV causes a
clinical illness that can be divided into three stages.
Following an incubation period of 3–6 days, patients
experience high fevers accompanied by prostration,
headache, and malaise lasting 3–4 days. After a 24- to
48-h period during which symptoms remit, 15% of pa-
tients enter the third stage of illness (period of intoxica-
tion) marked by jaundice, fever, relative bradycardia, and
a hemorrhagic diathesis, which can progress to multior-
gan failure involving the liver, kidney, and heart (Monath,
1999).
1 To whom correspondence and reprint requests should be ad-
dressed at CIDVR, Room S5-326, Univ. of Massachusetts Medical151Although antivirals such as interferon and ribavirin as
well as certain amaryllidaceae compounds have shown
promise in vitro (Gabrielsen et al., 1992; Monath, 1987),
treatment for yellow fever remains supportive. Public
health efforts have concentrated on preventive measures
that focus on the administration of the YFV vaccine to
persons who may be exposed to YFV through work,
travel, or habitation in endemic areas.
The YFV vaccine, a live attenuated vaccine (strain 17D)
derived from the human isolate Asibi, has been admin-
istered to over 300 million people with a minority of
recipients experiencing local reactions such as redness
or tenderness at the site (Moss-Blundell et al., 1981;
Pivetaud et al., 1986) and encephalitis being very rarely
reported in young infants (Louis et al., 1981; Stuart, 1956).
Recent reports however have suggested that yellow fe-
ver vaccine, in rare instances, can cause illness that
resembles infection with wild-type virus, especially in the
elderly (Chan et al., 2001; Martin et al., 2001; Vasconcelos
et al., 2001).
Effectiveness of the vaccine in humans and animals
has been attributed to the development of complement
fixing antibodies to the NS1 protein and neutralizing
antibodies to the E structural protein with a duration of
protection as long as 35 years (Brandriss et al., 1990;
Lobigs et al., 1987; Poland et al., 1981). In animal studies,
active immunization with the YFV structural protein E orKey Words: yellow fever virus; vaccine; HLA-B35; flaviviru
protein; NS3 protein.
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with monoclonal antibodies to these proteins has been
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shown to protect mice and monkeys against lethal YFV
infection (Brandriss et al., 1986; Putnak and Schlesinger,
1990; Schlesinger et al., 1986, 1993). The best evidence
of the efficacy of the YFV vaccine in humans is based on
epidemiological studies showing a decrease in inci-
dence of YFV in affected areas after introduction of the
vaccine (Durieux, 1956; Soper, 1938).
Our laboratory is interested in analyzing YFV-specific
CD8 T cell responses in YFV vaccine recipients to
better understand the role of T lymphocytes in protection
after immunization. Strong evidence that CD8 T cells
are important for viral clearance comes from murine
models of influenza virus and LCMV infections (Doherty,
1996; Kuwano et al., 1990). Human data in HIV, CMV, and
EBV infections are also suggestive of an important role
for virus-specific CD8 T cells (Cheynier et al., 1992;
Pinto et al., 1995; Riddell et al., 1992; Rooney et al., 1995;
Rowland-Jones et al., 1998, 1993; Walter et al., 1995). In
this article, we characterize YFV-specific CTL responses
in the peripheral blood mononuclear cells (PBMC) of four
individuals who received the live attenuated YFV 17D
vaccine. Proliferation and cytolytic responses to YFV
were demonstrated in all individuals. We isolated 13
CD8 T cell lines, the majority of which were HLA-B35-
restricted and directed against epitopes on the YFV
structural protein E and the nonstructural proteins NS1,
NS2b, and NS3. To our knowledge, this is the first report
of YFV-specific human T cell responses.
RESULTS
Proliferative responses of PBMC to yellow fever
antigen
To assess the induction of proliferation responses to
YFV by vaccination, we collected PBMC from four healthy
donors (A–D) prevaccination (Day 0) and at various time
points postvaccination; Day 0 PBMC served as a nega-
tive control. These samples were thawed and then cul-
tured with YFV antigen at various dilutions for 6 days and
[3H]thymidine incorporation was measured. The results
are shown in Table 1. Day 0 PBMC from Donors A, C, and
D showed no proliferation to yellow fever antigen (stim-
ulation index ((SI)  3), indicating that none of these
donors had previous exposure to yellow fever virus.
There was a low level of preexisting response to YFV
antigen (SI  1.3–3.5) in Day 0 PBMC of Donor B, which
may be related to prior immunization with inactivated
Japanese encephalitis vaccine. All four subjects devel-
oped proliferation responses to YFV (SI  3) after vacci-
nation; in three of four subjects SI values were 30. For
Donor A, multiple postvaccination PBMC samples were
tested in the same assay; proliferation responses to YFV
were evident, compared to the donor’s prevaccination
PBMC, at 14 days postvaccination.
Yellow fever specific cytolytic activity in bulk culture
YFV-specific cytolytic activity in postvaccination PBMC
samples was measured 14 days after in vitro stimulation
with infectious YFV using as target cells autologous
BLCLs infected with recombinant vaccinia viruses ex-
pressing portions of the YFV genome. Results from these
experiments are shown in Table 2. For Donors A and C,
bulk culture CTL demonstrated much greater lysis of
target cells infected with the vaccinia construct Vp729
TABLE 1
Yellow Fever Specific Proliferative Responses of PBMC
from Yellow Fever Vaccine Recipientsa
Donor
Days
postvaccination
Stimulation indexb at
indicated Ag dilution
1:80 1:160
Ac 0 1.3 0.5
7 0.1 0.7
14 9.3 4.0
28 10.6 8.1
71 4.8 9.8
Bc 0 1.3 3.5
180 39.0 31.0
C 0 1.2 1.6
56 376.0 237.0
D 0 2.2 0.9
29 58.3 47.0
a PBMC (2  105 cells) were incubated for 6 days in the presence of
serial dilutions of yellow fever antigen. Cells were then pulsed with 1.25
uCi of [3H]TdR for 8 h and thymidine incorporation was measured.
b Stimulation index (SI) is calculated as mean cpm of cultures with
yellow fever antigen/mean cpm of culture with control antigen.
c These donors have received the inactivated Japanese encephalitis
vaccine.
TABLE 2
Recognition of YFV Proteins by Bulk Culture Cytotoxic T Cells
from Yellow Fever Vaccine Recipientsa
Donor (days
postvaccination)
% Specific 51Cr release of target
cells infected withb
Vp729
(E, NS1,
NS2a, NS2b)
VAC3B
(NS3
199–433)
VAC3C
(NS3
398–623)
VAC
control
A (71) 65 NT NT 11
B (56) 69 53 44 43
C (55) 61 11 11 13
D (64) 24 16 21 11
a PBMC obtained at the indicated time point postvaccination were
stimulated with YFV on Day 0 and 7 of culture and tested on Day 14 of
culture at an E/T ratio of 60:1. Results are derived from three separate
experiments.
b YFV proteins encoded by recombinant vaccinia viruses Vp729,
VAC3B, and VAC3C are shown in parentheses.
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than target cells infected with a control vaccinia virus.
Vp729 expresses the structural protein E and the non-
structural proteins NS1, NS2a, and NS2b. For Donor B,
background lysis of target cells infected with control
vaccinia virus was relatively high, but lysis of Vp729-
infected target cells was significantly higher (69% vs
43%). Donor D PBMC showed a lower level of recognition
of the E, NS1, NS2a, and NS2b proteins. Bulk culture CTL
from Donors B and D showed only slightly higher lysis of
target cells infected with recombinant vaccinia viruses
expressing portions of the YFV NS3 protein than target
cells infected with control vaccinia virus. These experi-
ments demonstrate that cytotoxic T cell responses to
YFV proteins (E, NS1, NS2a, or NS2b) can be detected in
the PBMC of donors who received the YFV vaccine.
Isolation of yellow fever specific CTL lines
To define epitopes recognized by YFV-specific CTL, we
isolated YFV-specific T cell clones by limiting dilution.
Wells positive for growth were screened for lysis of target
cells infected with vaccinia recombinants expressing
portions of the yellow fever genome. All YFV-specific CTL
lines isolated were found to be CD8 (data not shown).
We characterized in detail 13 YFV-specific CTL lines
derived from four donors (Table 3 and data not shown).
We isolated other T cell lines that showed similar pat-
terns of recognition as one or more of the cell lines
shown.
Several YFV-specific CTL lines were isolated from the
PBMC of Donor A obtained 10 weeks postvaccination.
Cell lines A3.1 and A3.2 only recognized target cells that
expressed the nonstructural protein NS2b (Vp729) and
failed to recognize target cells that only expressed either
the structural proteins preM and E (Vp869 and Vp730) or
the nonstructural proteins NS1 and NS2a (Vp725). Cell
lines A3.14 and A3.5 only recognized target cells ex-
pressing NS1 or NS2a (Vp729 and Vp725). Cell line A3.13
only recognized target cells expressing the structural
protein E (Vp729, Vp869, and Vp730). Cell line B3.2 was
isolated from Donor A PBMC obtained 56 days postvac-
cination and only recognized target cells expressing
amino acids 199–433 of the NS3 protein (VAC3B).
YFV-specific CTL lines were isolated from the PBMC of
Donor B obtained 8 weeks postvaccination. Cell lines
A3.7 and A10.29 only recognized target cells expressing
amino acids 199–433 of the nonstructural protein NS3
(VAC3B). Cell line A10.52 recognized target cells infected
with the recombinant vaccinia virus expressing the E,
NS1, NS2a, and NS2b proteins (Vp729), but not target
cells infected with recombinant vaccinia viruses ex-
pressing portions of the NS3 protein.
YFV-specific CTL lines were isolated from the PBMC of
Donor C obtained 8 weeks postvaccination. Cell line A1.4
only recognized target cells expressing NS2b (Vp729).
Cell line A1.5 only recognized target cells expressing
amino acids 398–623 of the nonstructural protein NS3
(VAC3C). Cell line A10.39 recognized two vaccinia recom-
binants, Vp729 and VAC3A, suggesting that this CTL line
was a mixture of two subpopulations, one recognizing
NS2b and one recognizing amino acids 1–232 of NS3.
The one YFV-specific CD8 T cell line that was iso-
lated from the PBMC of Donor D obtained 2 months
TABLE 3
Recognition of YF Proteins by CTLs Generated from PBMC of YF Vaccine Recipientsa
Donor
Cell
line
% Specific 51Cr release of target cells infected with
Protein
recognized
Vp729
(E, NS1, NS2a, NS2b)
Vp869
(PrM, E)
VAC3A
(NS3 1–232)
VAC3B
(NS3 199–433)
VAC3C
(NS3 398–623)
Vp725
(NS1, NS2a)
Vp730
(E)
A A3.1 59 3 NT NT NT 4 9 NS2b
A3.2 63 3 NT NT NT 0 2 NS2b
A3.5 38 2 NT NT NT 100 4 NS1/2a
A3.14 68 2 NT NT NT 86 3 NS1/2a
A3.13 43 61 NT NT NT 4 76 E
B3.2 1 NT NT 83 1 NT NT NS3
B A3.7 3 NT NT 22 1 NT NT NS3
A10.29 1 NT NT 38 2 NT NT NS3
A10.52 46 NT 3 6 2 NT NT ndb
C A1.4 54 NT 2 2 1 3 1 NS2b
A10.39 22 NT 37 5 3 2 4 Mixed
A1.5 1 NT 0 1 60 NT NT NS3
D A10.34 3 NT 3 54 59 NT NT NS3
a Effector cells were added to autologous target cells infected with vaccinia recombinant viruses expressing portions of the yellow fever virus at
an E/T ratio of 5 or 10. The T cell lines shown here were tested in separate experiments. Underlined values represent significant levels of lysis. NT,
not tested.
b nd, not determined. This cell line was later found to recognize an epitope on the NS2b protein.
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postvaccination, A10.34, recognized target cells infected
with overlapping regions of the NS3 protein, VAC3B (aa
199–433) and VAC3C (aa 398–623), but not target cells
infected with Vp729 or VAC3A, suggesting that the
epitope recognized is in the region of amino acids 398–
433 of the NS3 protein.
In summary, we isolated three CD8 T cell lines that
recognized the nonstructural protein NS2b, five CD8 T
cell lines (from four donors) that recognized the non-
structural protein NS3, two CD8 T cell lines that recog-
nized the nonstructural proteins NS1 or NS2a, and one
CD8 T cell line that recognized the structural protein E.
HLA restriction of yellow fever specific
CD8 T cell lines
The HLA restriction of YFV-specific CD8 T cell lines
from two of the four YFV vaccine recipients (Donor A and
B) was determined by testing each cell line against a
panel of partially matched allogeneic BLCL infected with
the vaccinia recombinant Vp729, which expresses the
structural protein E and the nonstructural proteins NS1,
NS2a, and NS2b. Results from five of the CD8 T cell
lines isolated from Donor A are shown in Table 4. All five
CD8 T cell lines recognized CB target cells, which
shared HLA-B35 and HLA-Cw4, but none recognized TG
target cells, which shared HLA-Cw4, suggesting that
these T cell lines were HLA-35-restricted. However, only
three of the five T cell lines recognized Donor B BLCL,
which also shared HLA-B35. To explain these results, we
tested these cell lines for recognition of Vp729-infected
HMY cells stably transfected with either HLA B*3501 or
B*3502. Although the parental HMY cells were previously
reported to express low levels of HLA B*3503 (Zemmour
et al., 1992), these cells were not recognized by any of
the T cell lines. Cell lines A3.1 and A3.2 lysed HMY cells
that expressed either HLA B*3501 or B*3502. Cell lines
A3.5 and A3.14 only recognized the HMY target cells that
expressed HLA B*3501, while cell line A3.14 only recog-
nized the HMY target cells that expressed HLA B*3502.
Results of other experiments demonstrated that the Do-
nor A T cell line B3.2 and the Donor B T cell lines A3.7
and A10.29 lysed only NS3 peptide-pulsed HMY cells
that expressed HLA B*3502, while the Donor B T cell line
A10.52 recognized NS2b peptide-pulsed HMY cells ex-
pressing either HLA B*3501 or B*3502 (data not shown).
Analysis of Donor A and B HLA-B35 alleles
The results above showed that HLA-B35-restricted
CD8 T cell lines derived from the PBMC of Donors A
and B recognized different HLA-B35 alleles. To better
understand this result, we analyzed the HLA-B35 sub-
types in these donors by direct sequencing of the PCR
product of the HLA B genes from Donors A and B. This
analysis showed that Donor B was homozygous for HLA
B*3502. Direct sequencing of the PCR product of the
HLA-B genes from Donor A suggested that Donor A was
heterozygous for B*3502 and B*3503. To confirm this, we
cloned the PCR product and determined the nucleotide
sequence of four subclones. Three of the four subclones
were B*3502 and one was B*3503. Restriction enzyme
digestion was performed to confirm that the PCR product
had two different sequences. HLA B*3502 cDNA has two
NarI and two RsaI restriction enzyme sites, while HLA
B*3503 cDNA has three NarI and one RsaI restriction
enzyme sites. Digestion of the PCR product with NarI and
RsaI followed by 3% agarose gel electrophoresis dem-
onstrated the fragments expected from both cDNAs (data
not shown). These results confirmed that Donor A was
heterozygous for B*3502 and B*3503.
Localization of CTL epitopes
To identify the specific peptides recognized by YFV
specific CD8 T cell lines, each cell line was tested for
recognition of target cells pulsed with synthetic peptides.
In the case of the NS2b and NS3 proteins, the 20-mer
TABLE 4
HLA Restriction of YFV-Specific T Cell Lines Isolated from Donor Aa
Target cell
HLA class I
haplotypes
% specific lysis by indicated CD8 T cell lines
A3.1 A3.2 A3.5 A3.13 A3.14
Autologous A3, A24, B35, Cw4 51 82 50 51 66
Donor B A1, A24, B44, B35, Cw4 35 45 8 74 5
CB A2, A23, B35, Cw4 49 64 45 44 61
TG A23, A29, B7, B44, Cw4 5 1 7 5 1
HMY 35.01 B*3501 47 29 41 6 50
HMY 35.02 B*3502 35 32 9 34 14
HMY Control 2 3 2 1 1
a Effector cells were tested for recognition of autologous or partially HLA-matched allogeneic target cells infected with recombinant vaccinia virus
Vp729 expressing the E, NS1, NS2a, and NS2b proteins. The T cell clones shown were tested in separate experiments. The HLA alleles shared with
allogeneic target cells are underlined.
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peptides overlapped by 10 amino acids and covered the
sequence of the entire protein or, for NS3, that portion
expressed by the recombinant vaccinia virus. For the E
and NS1 proteins, we selected for synthesis 19–21-mer
peptides that contained sequences of nine amino acids
predicted to bind well to HLA B*3501. Once a peptide
recognized by the CTL was identified, we mapped the
epitope further using truncations of the peptide 9–12
amino acids in length. Results are summarized in
Table 5.
Donor A T cell lines A3.1 and A3.2 recognized the
20-mer peptide corresponding to residues 101–120 of the
NS2b protein (Fig. 1A) and efficiently recognized the
predicted 9-mer within this region (residues 110–118,
HPFALLLVL) at concentrations of 0.25 g/ml. This
9-mer peptide was also recognized by the Donor B T cell
line A10.52 (data not shown). The Donor A T cell line
A3.13 recognized the 21-mer peptide corresponding to
residues 329–349 of the E protein (Fig. 1B) and efficiently
recognized the predicted 9-mer within this region (resi-
dues 332–340, IPVIVADDL) at concentrations of 0.0025
g/ml (Fig. 2). The Donor A T cell line A3.14 recognized
the 20-mer peptide corresponding to residues 351–370
of the NS1 protein (data not shown); this T cell line also
recognized the smaller peptides NS1 (355–365) and NS1
(356–366), but did not recognize the peptide NS1 (357–
368) (Fig. 3). These results demonstrate that the epitope
recognized by T cell line A3.14 lies within residues 356–
365 of NS1 (HAVPFGLVSM), with the N-terminal H resi-
due necessary for recognition. The Donor A T cell line
B3.2 and the Donor B T cell lines A3.7 and A10.29
recognized the 20-mer peptide corresponding to resi-
dues 341–360 of the NS3 protein (data not shown). The
pattern of recognition of truncations of this peptide (Fig.
4) indicate that the epitope recognized by these T cell
lines lies within residues 349–358 of NS3 (WNTGHD-
WILA).
In summary, we identified CTL epitopes on the YFV E,
NS1, NS2b, and NS3 proteins. Of note, the same epitopes
on the NS2b and NS3 proteins were recognized by T cell
lines derived from two HLA-B35 positive donors.
TABLE 5
Summary of Epitopes Recognized by Human YFV-Specific
CD8 CTL Lines
Donor
CTL
line
Protein
recognized
AA position
of epitope Sequence
A A3.1 NS2b 110–118 HPFALLLVL
A3.2 NS2b 110–118 HPFALLLVL
A3.14 NS1 356–365 HAVPFGLVSM
A3.13 E 332–340 IPVIVADDL
B3.2 NS3 351–358 TGHDWILA
B A3.7 NS3 349–358 WNTGHDWILA
A10.29 NS3 349–358 WNTGHDWILA
A10.52 NS2b 110–118 HPFALLLVL
FIG. 1. Localization of the epitopes recognized by YFV-specific CD8
T cell lines. (A) T cell line A3.1 from Donor A was tested for recognition
of autologous target cells incubated with peptides derived from the
sequence of the YFV NS2b protein. (B) T cell line A3.13 from Donor A
was tested for recognition of autologous target cells incubated with
peptides derived from the sequence of the YFV E protein. vP729 is the
recombinant vaccinia virus expressing the YFV E, NS1, NS2a, and NS2b
proteins.
FIG. 2. Recognition of the optimal epitope on the YFV E protein by T
cell line A3.13 from Donor A. Autologous target cells were infected with
vP729 expressing the YFV E, NS1, NS2a, and NS2b proteins or were
incubated with the indicated concentration of the YFV E (332–340)
peptide (IPVIVADDL).
FIG. 3. Localization of the epitope on the YFV NS1 protein recognized
by Donor A T cell line A3.14. Target cells were autologous BLCL
incubated with the indicated peptide (25 g/ml). The E/T ratio was 10.
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Kinetics of YFV specific T cell responses
We used the ELISPOT assay to quantitate interferon
(IFN) production of YFV-specific CD8 T cells at the
single cell level using thawed pre- and postvaccination
PBMC from Donors A and B stimulated with the mapped
E, NS1, NS2b, and NS3 epitopes (Fig. 5). Pre- and post-
vaccination PBMC were tested in the same assays.
For Donor A, no YFV specific T cells were detected at
Day 0. The frequency of circulating T cells to the four
mapped YFV epitopes after vaccination ranged between
1/2752 to less than 1/300,000 PBMC dependent on both
the time point postvaccination and the epitope tested.
Responses to all four YFV epitopes were detected as
early as 14 days postvaccination. The strongest re-
sponses were seen with the NS1 (355–366) peptide (1/
2752–1/5357 PBMC) and the NS2b (110–118) peptide
(1/4478–1/14,286 PBMC), and the frequency of T cells
specific for these epitopes remained stable up to 19
months postvaccination. Both of these epitopes were
more immunodominant than either the E (1/9677–1/
50,000 PBMC) or the NS3 (1/25,000—less than 1/300,000
PBMC) epitopes.
For Donor B, there was an absence of YFV peptide
specific T cells detected at Day 0 except to the NS2b
epitope (1/150,000). We observed minimal or no T cell
response to the NS1 epitope (1/100,000) at any time
point. Responses to the E and the NS2b epitopes were
detected as early as 2 weeks postvaccination, whereas
the response to the NS3 epitope was first detected at 1
month postvaccination. The responses to the E (1/7500–
1/75,000 PBMC), NS2b (1/8695–1/150,000 PBMC), and
NS3 (1/9677–1/75,000 PBMC) epitopes were similar over
the time period tested, with a slight decline noted at 17
months postvaccination.
DISCUSSION
We describe here the T cell responses to YFV in four
volunteers who received the 17D live attenuated YFV
vaccine. Bulk culture proliferation and cytolytic re-
sponses to YFV were detected in PBMC obtained post-
FIG. 4. Localization of the epitope on the YFV NS3 protein recognized
by Donor A T cell line B3.2 and T cell lines A3.7 and A10.29 from Donor
B. Target cells were autologous BLCL pulsed with the indicated peptide
(25 g/ml). The E/T ratio was 5.
FIG. 5. Kinetics of antigen-specific T cell frequency up to 18 months after immunization with yellow fever vaccine in Donor A (top) and Donor B
(bottom). PBMC from each of the donors were cultured for 18–20 h with the E, NS1, NS2b, or NS3 peptides at a concentration of 5 g/ml and tested
in a standard IFN Elispot assay. Each point represents the inverse frequency of antigen specific T cells to the indicated peptide.
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vaccination in all four subjects studied. We characterized
13 YFV-specific CD8 T cell lines and identified four
HLA-B35-restricted T cell epitopes that were distributed
on four different YFV proteins—E, NS1, NS2b, and NS3.
Using the IFN enzyme-linked immunospot (ELISPOT)
assay, we examined the kinetics of the T cell response to
these four epitopes in two HLA-B35 subjects between
14 days and 19 months postvaccination. To our knowl-
edge, this is the first description of human T cell re-
sponses to YFV and the first identification of CD8 T cell
epitopes on YFV proteins.
All of the T cell epitopes we defined were fully recog-
nized in the context of HLA B35. HLA B35 is a relatively
common allotype found in 10–28% of the population (Ra-
gupathi et al., 1995). The peptide binding motif for HLA
B*3501 and B*3503 consists of anchor residues at posi-
tion 2 (P) and position 9 (F, M, or L) (Rammensee et al.,
1995; Steinle et al., 1995). The characteristics of peptide
binding to HLA B*3502 has not been described. The
NS2b (HPFALLLVL) epitope fits the HLA B*3501/3503
binding motif and could be recognized by Donor A T cell
lines in the context of B*3501 and B*3502. The E (IPVI-
VADDL) epitope also fits the B*3501/3503 binding motif
and was recognized by Donor A T cell line A3.13 in the
context of B*3502. Although a 12-mer peptide recognized
by the NS3-specific T cell clones (residues 347–358,
EPWNTGHDWILA) contained a potential proline anchor
residue, the mapped epitope lacked this residue. The
NS1 epitope contains a proline residue, but our results
show that this residue does not lie at position 2 of the
peptide, since at least three residues N-terminal to the
proline were required for recognition. For these peptides,
other residues may contribute to the binding to HLA-B35.
Schonbach et al. (1996) found that aliphatic hydrophobic
side chains (Leu, Ile, Val, Met) at positions 3, 5, and 8
were found to enhance binding of 10-mer peptides to
HLA B*3501. The 10-mer NS1 peptide contains hydropho-
bic valine residues at positions 3 and 8, and the 10-mer
NS3 peptide (WNTGHDWILA) contains a hydrophobic
isoleucine residue at position 8. The 8-mer NS3 peptide
(TGHDWILA), which was recognized by some T cell lines,
has other preferred residues for 9-mer peptides at posi-
tions 4 (D) and 6 (I), as well as a W residue at position 5
that has been noted in another HLA-B35-restricted T cell
epitope (Koziel et al., 1992).
Several of the T cell clones isolated from Donor A
recognized peptides presented by HLA B*3501, although
this donor’s genotype was HLA B*3502/B*3503; some of
the T cell clones recognized peptides when presented by
either HLA B*3501 or B*3502. These findings most likely
reflect the subtle amino acid differences between the
HLA B35 alleles. Sequence variations among the B35
subtypes are clustered in amino acid positions 94, 95, 97,
109, 114, and 166 (Beck et al., 1995; Ragupathi et al.,
1995). The variations between the B*3501, B*3502, and
B*3503 subtypes occur in amino acids 109, 114, and 116,
which lie in the  sheet of the peptide binding pocket
within the 2 domain of the class I molecule. HLA
B*3502 differs from B*3501 at positions 109, 114, and 116,
while B*3503 differs from B*3501 only at position 116.
These amino acids are involved in peptide side chain
interactions in the C (97 and 114), D (114), E (97 and 114),
and F (116) pockets (Ragupathi et al., 1995). Thus, the
differences we observed in peptide recognition in the
context of different HLA-B35 alleles likely reflect effects
on peptide binding. The failure of Donor A NS1-specific T
cell lines (A3.5 and A3.14) to recognize Donor B target
cells (Table 4) suggests that this epitope can be pre-
sented by either HLA B*3501 or B*3503 but not by HLA
B*3502 and is consistent with the observation that Donor
B showed no significant T cell response to this epitope in
ELISPOT assays (Fig. 5).
The IFN ELISPOT assays showed the frequency of T
cells specific for several of the HLA-B35-restricted T cell
epitopes to be in the range of 1 in 10,000 PBMC or
higher. T cell responses to the E and NS2b epitopes
were prominent in both HLA-B35 subjects studied,
suggesting that these are important targets for the T cell
response in HLA-B35 individuals. The NS1 epitope
was immunodominant in Donor A, but, as noted above, it
was not recognized to any significant level in Donor B,
suggesting that this epitope may be less relevant to the
YFV-specific T cell response in the general population. T
cell responses to the NS3 epitope were detected in both
subjects, but were subdominant; this was somewhat
surprising to us because the NS3 protein of dengue
virus, a related flavivirus, appears to be a dominant
target for the CD4 and CD8 T cell response (Livingston
et al., 1995; Mathew et al., 1998; Zivny et al., 1999).
Although both Donors A and B had received the inacti-
vated Japanese encephalitis (JE) vaccine, we do not
expect this to have altered our findings because inacti-
vated vaccines are poor inducers of CD8 T cell re-
sponses and would not be expected to contain nonstruc-
tural proteins. Prior studies have found no differences in
replication of YFV 17D or antibody responses to YFV in
vaccine recipients with previous exposure to JE virus
(Sweet et al., 1962; Wisseman et al., 1962).
The frequency of YFV-specific T cells we detected is
comparable to the frequency of T cells specific for CD8
T cell epitopes on influenza A virus as measured by IFN
ELISPOT assays (Jameson et al., 1999). However, in the
case of influenza virus there is a high likelihood of
repeated exposure that may boost virus-specific T cells.
Most other data on the frequency of virus-specific CD8
memory T cells has related to persistent viral infections
such as HIV, EBV, and CMV, where virus-specific T cells
make up as much as 3–5% of all circulating CD8 T cells
after the acute phase of infection (Callan et al., 1998;
Dalod et al., 1999a,b; Kern et al., 1998; Tan et al., 1999).
Data on nonrecurring acute viral infections is much more
limited; one study using intracellular IFN staining re-
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ported that measles virus-specific T cells represented a
median of 0.24% of circulating CD8 T cells in healthy
adults decades after the original infection (Nanan et al.,
2000).
Because exposure to YFV is geographically limited,
immunization with the YFV 17D vaccine may provide an
ideal system to study the kinetics of the human T cell
response to an acute virus infection. We found that YFV
peptide-specific T cells were induced as early as 14 days
postvaccination and that the frequency of these T cells
was maintained at a relatively stable level for up to 18
months postvaccination. The kinetics of the T cell re-
sponse to acute virus infections have been well charac-
terized in laboratory mice, including to other flaviviruses.
For example, van der Most et al. (2000) studied the T cell
response to a YFV-dengue virus chimera in BALB/c mice
using intracellular IFN staining; memory CD8 T cells
specific for an epitope on the dengue E protein repre-
sented 1/700 CD8 T cells at 100 days after immuniza-
tion. In contrast, there have been few studies that have
examined the kinetics of the memory T cell response to
immunization or natural infection in humans. Pathan et
al. (2000) reported that the CD8 T cell response to a
Mycobacterium tuberculosis ESAT6 epitope remained
stable over a 2-year period in an asymptomatic house-
hold contact. Rahman et al. (2000) assessed the T cell
response to pooled hepatitis B peptides at various time
points up to 32 weeks after vaccination with the recom-
binant hepatitis B vaccine. They detected a transient
increase in peptide-specific T cell frequencies 2 weeks
after booster immunization that was not sustained. Our
group has found increases in the frequency of influenza
A virus peptide-specific T cells at 14 and 56 days after
receipt of an adjuvanted influenza vaccine (unpublished
data); longer term follow-up was not available.
There is no data to permit a comparison between the
vaccine-induced T cell responses to YFV we have mea-
sured with the T cell response to infection with wild-type
YFV. Furthermore, there is no data to establish the role of
vaccine-induced T cell responses in the protective effi-
cacy of the YFV 17D vaccine. However, the four CTL
epitopes we have identified are well conserved among
isolates of YFV. For the E epitope, sequence data are
available for comparison from over 20 viruses (Chang et
al., 1995); the sequence is fully conserved in all isolates
from genotypes I and IIA, whereas there is a conserva-
tive substitution of M for I at position 4 in the epitope in
isolates from genotype IIB. For the other epitopes, only
four to five wild-type YFV sequences are available for
comparison. The sequences of the NS1 and NS3
epitopes are fully conserved. The sequence of the NS2b
epitope is fully conserved in three of the published se-
quences, while there is a single nonconservative substi-
tution of S for F at position 3 in a strain of YFV isolated
from a patient from Cote d’Ivoire in 1982 (strain 85-82H,
GenBank Accession No. U54798).
In vivo cell depletion experiments by van der Most et
al. (2000) demonstrated a role for both CD4 and CD8
T cells in the protective efficacy of the YFV/dengue chi-
mera against intracerebral challenge with dengue virus
infection in mice. Mice immunized with a DNA vaccine
against influenza A virus were protected against lethal
challenge when the frequency of NP epitope-specific T
cells was greater than 1/100,000 spleen cells (Fu et al.,
1999). One group estimated the circulating frequency of
CTL in Gambian prostitutes who remained seronegative
despite multiple exposures to HIV at 1/3200–1/50,000,
offering some correlate of protection from illness (Row-
land-Jones et al., 1998). These data, along with the evi-
dence of sequence conservation with wild-type YFV
strains, support the hypothesis that the CD8 T cell
responses to YFV 17D vaccine we observed could con-
tribute to protection against illness.
Given the conserved features of flavivirus genome
organization and the safety and effectiveness of the YFV
vaccine, there has been interest in developing vaccines
against other flavivirus infections, such as dengue and
Japanese encephalitis, based on live attenuated chi-
meric viruses using the YFV genetic backbone (Guirak-
hoo et al., 2000; van Der Most et al., 2000). An improved
understanding of immune responses induced by the YFV
vaccine will help us understand how preexisting immu-
nity to the YFV genetic component might alter the effec-
tiveness of these chimeric vaccines.
MATERIALS AND METHODS
PBMC donors
Blood was obtained from four healthy individuals who
had received the live attenuated 17D yellow fever vac-
cine after informed consent was obtained. Donors A and
B received the inactivated Japanese encephalitis vaccine
14 months after and 4 years prior to the administration of
the yellow fever vaccine, respectively. Donor A PBMC
were collected prevaccination and at the following time
points postvaccination—7 days, 14 days, 4 weeks, 10
weeks, 7 months, 11 months, 15 months, and 19 months.
Donor B PBMC were collected prevaccination and at the
following time points postvaccination—7 days, 12 days,
4 weeks, 8 weeks, 6 months, 10 months, and 17 months.
Donor C PBMC were collected prevaccination and at 8
weeks and 6 months postvaccination. Donor D PBMC
were collected prevaccination and at the following time
points postvaccination—4 weeks, 9 weeks, and 6
months. The HLA class I alleles of these donors are as
follows: Donor A—A3, A24, B35, Cw4; Donor B—A1, A24,
B35, Cw4; Donor C—A2, A11, B40, Cw3, Cw7; Donor
D—A2, A68, B27, B40, Cw2. PBMC were purified by
Ficoll–Hypaque density gradient centrifugation and cryo-
preserved until needed.
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B lymphoblastoid cell lines (BLCL)
PBMC (1–4  106) were thawed and then cultured in
RPMI 1640 supplemented with penicillin, streptomycin,
L-glutamine, HEPES, and 20% FBS in the presence of a
1:3 dilution of EBV from B95-8 cells (American Type
Culture Collection) in 24-well flat bottom plates (Becton
Dickinson, Franklin Lakes, NJ) as previously described
(Bukowski et al., 1989). Cyclosporine A was added at
1 g/ml.
Proliferative responses of PBMC to viral antigen
PBMC (1  105) were thawed and then cultured with
inactivated YFV 17D antigen or control antigen, which
were prepared in Vero cells as described (Kurane et al.,
1989b), at various dilutions in 0.2 ml AIM V medium
(GIBCO-BRL) containing 10% human AB serum (NABI,
Boca Raton, FL) in 96-well round-bottom microtiter plates
(Becton Dickinson) at 37°C for 6 days. The cells were
pulsed with 1.25 Ci [3H]thymidine for 8 h at 37°C before
they were harvested using a multiharvester (Skatron Inc.,
Sterling, VA). [3H]thymidine incorporation was measured
in a liquid scintillation counter (1205 Betaplate; Pharma-
cia, Wallac Oy, Finland). Stimulation index was calculated
as follows: mean cpm of cultures with viral antigen/mean
cpm of cultures with control antigen.
In vitro stimulation of PBMC
PBMC obtained between 8 and 10 weeks postvacci-
nation (2–5  106 per well) were thawed and then resus-
pended in 1.5 ml of AIMV containing 15% human AB
serum in a 24-well plate (Becton Dickinson). YFV (YF-
VAX, Connaught Laboratories) was propagated in Vero
cells and the infectious virus stock was added to PBMC
at a 1:160 final dilution. Recombinant human IL-2 (20
U/ml) was added on Day 4 or 5 in 1 ml fresh AIMV
containing 10% human AB serum and the medium was
replenished every third day thereafter. Bulk culture 51Cr
release assays were performed between Days 7 and 14
of culture. PBMC were restimulated on Day 7 with infec-
tious YFV (1  108 IU/ml) and 5  106 gamma-irradiated
autologous PBMC.
CTL lines
YFV-specific CTL lines were established by limiting
dilution plating as previously described (Kurane et al.,
1989a). Briefly, PBMC stimulated in vitro with infectious
YFV, as described above, were plated at 1, 3, 10, or 30
cells/well in 96-well round bottom plates (Becton Dick-
inson) in 0.2 ml of AIMV-15% FBS with 0.1 g/ml anti-CD3
antibody (12F6; a gift of Dr. Johnson Wong, MGH), 50
U/ml rhIL-2, and 1  105 gamma-irradiated allogeneic
PBMC. Medium was replaced every 3 days and wells
were restimulated with anti-CD3 and gamma-irradiated
feeder cells every 14 days. Individual wells were tested
for recognition of target cells infected with recombinant
vaccinia viruses expressing YFV proteins in a 51Cr re-
lease assay, and cells in positive wells were expanded
and restimulated as described above. Surface expres-
sion of CD8 was determined by flow cytometry with
fluorescein isothiocyanate-conjugated antibodies (Bec-
ton–Dickinson).
HMY cell lines
Hmy2.C1R (Hmy) is a human plasma cell line that
lacks endogenous HLA A and B antigens (Storkus et al.,
1987). Hmy lines transfected with B35.01 or B35.02 were
generated as previously described (Ooba et al., 1989)
and were kindly provided by Masafumi Takaguguchi
(University of Tokyo, Tokyo, Japan).
Recombinant vaccinia viruses
Recombinant vaccinia viruses (Vp729, Vp869, Vp725,
Vp730) expressing YFV proteins were kindly provided by
J. Tartaglia, Virogenetics Corp., Troy, NY (Pincus et al.,
1992). Vp729 expresses the 19 aa signal sequence pre-
ceding the N terminus of E as well as the structural
protein E and the nonstructural proteins NS1, NS2a, and
NS2b. Vp869 expresses the 21 aa signal sequence pre-
ceding the N terminus of the structural protein precursor
prM as well as prM and E proteins. Vp725 expresses the
17 aa signal sequence preceding the N terminus of
nonstructural protein NS1 and the nonstructural protein
NS1 and NS2a. Vp730 expresses the 19 aa signal se-
quence preceding the N terminus of the E protein as well
as the structural protein E. VAC3A, VAC3B, and VAC3C
were made by our laboratory using methods previously
described (Saikh et al., 1993). VAC3A expresses amino
acids 1–232 of the nonstructural protein NS3. VAC3B
expresses amino acids 199–433 of the nonstructural pro-
tein NS3. VAC3C expresses amino acids 398–623 of the
nonstructural protein NS3. A schematic of the recom-
binant vaccinia viruses used in this study is shown in
Fig. 6.
FIG. 6. Schematic of the recombinant vaccinia viruses containing
portions of the yellow fever genome used in our experiments.
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Synthetic peptides
Peptides corresponding to YFV sequences were syn-
thesized at the Protein Chemistry Core Facility at the
University of Massachusetts Medical School with an
automated Rainin Symphony peptide synthesizer. Pep-
tides varied from 8 to 20 amino acids in length. For the
nonstructural proteins NS2b and NS3, the synthetic pep-
tides were originally 20 amino acids in length and over-
lapped by 10 amino acids to encompass the entire pro-
tein. Smaller peptides were subsequently produced to
better define the epitopes. 20-mer peptides for the struc-
tural protein E and the nonstructural protein NS1 were
selected for synthesis on the basis of the results of an
algorithm to predict HLA-peptide binding (http://bimas.
dcrt.nih.gov).
Preparation of target cells
Virus-infected targets. BLCL (3  105) were infected
with recombinant vaccinia virus at a multiplicity of infec-
tion of 15 for 60 min at 37°C. The cells were then diluted
in 1 ml of RPMI 1640 containing 10% FBS for an addi-
tional 12–16 h. Target cells were then labeled with 0.25
mCi of 51Cr for 60 min at 37°C. Following labeling, the
cells were washed three times and resuspended at 1.5
104/ml in RPMI containing 10% FBS for use in cytotoxicity
assay. Autologous and partially HLA-matched allogeneic
BLCL were used as target cells in the assays.
Peptide pulsed targets. Uninfected BLCL were 51Cr
labeled as described above. Labeled cells were incu-
bated with 25 g/ml of peptide in 96-well round bottom
plates for 30 min at 37°C before the addition of effector
cells. The peptides remained in the wells for the duration
of the assay.
51Cr release assay
Effector cells were added to 1.5  103 51Cr-labeled
target cells at various effector cell/target cell (E/T) ratios.
Plates were incubated for 4.5 h at 37°C; supernatants
were harvested (Supernatant Collection System, Skatron
Instruments) and counted in a Hewlett–Packard 
counter. Specific lysis was calculated as 100  (experi-
mental release  spontaneous release)/(maximum re-
lease  spontaneous release). All assays were per-
formed in triplicate. Negative controls included target
cells infected with wild-type vaccinia virus and unin-
fected or unpulsed target cells.
Enzyme-linked immunospot assay for single cell IFN
secretion
ELISPOT assays were performed as described previ-
ously (Lalvani et al., 1997). Briefly, 96-well filtration plates
(MAIP S45; Millipore, Bedford, MA) were coated with 15
g/ml of mouse anti-human IFN monoclonal antibody
(NIB42 hybridoma) (Pharmingen, San Diego, CA). After
washing, RPMI containing 10% FBS was added at 100
l/well for 2 h at 37°C. PBMC were thawed and then
resuspended in RPMI containing 10% FBS at 3  105
cells/well. Peptides were added at a final concentration
of 5 g/ml with plates incubated for 18–20 h at 37°C.
Plates were washed with PBS and then with PBS con-
taining 0.05% Tween. Biotinylated mouse anti-human
IFN monoclonal antibody (4S.B3 antibody) (Pharmin-
gen) was then added at a final concentration of 2 g/ml
and plates were incubated at room temperature for 2 h,
followed by addition of 1:400 dilution of avidin peroxi-
dase (Sigma) at 100 l/well. Plates were then incubated
for 45 min at room temperature. Substrate (3-amino-9-
ethyl-carbazole-.15% H2O2; Sigma) was added and left for
10 min at room temperature. The precursor frequency
was calculated as (number of spots in wells containing
peptide  number of spots in wells with medium alone)/
(total number of cells per well). The number of spots in
the negative control wells (medium alone) ranged from
2 to 15. Experiments were performed in duplicate.
Determination of HLA B35 subtypes
Total RNA was isolated from BLCL using the Ultraspec
RNA Isolation System (Biotec Laboratories, Houston, TX).
To synthesize the cDNA, 2 g of total RNA was added to
the reaction mixture containing 50 mM Tris–HCl (pH 8.3
at 25°C), 75 mM KCl, 3 mM MgCl2, 10 mM DTT, 0.5 mM
dNTPs, 100 units of RNAguard (Pharmacia Biotech, Pis-
cataway, NJ), 0.5 g pd(T)12–18 (Pharmacia Biotech), and
500 units of M-MLV Reverse Transcriptase (Promega,
Madison, WI) in 100 l. The RT reaction was carried out
at 37°C for 60 min followed by heat inactivation at 95°C
for 10 min. HLA-B genes were amplified by an HLA-B
specific primer set: upstream primer (5P2T): 5-GGG CGT
CGA CGG ACT CAG AAT CTC CTC AGA CGC CGA G-3
(underlined base is different from original primer HLA-
5P2 (27)), and downstream primer (3B): 5-CCG CAA GCT
TCT GGG GAG GAA ACA CAG GTC AGC ATG GGA AC-3
(Zemmour et al., 1992). Primers 5P2T and 3B have SalI
and HindIII restriction enzyme sites for cloning, respec-
tively. PCR was performed using the GeneAmp XL PCR
Kit (PE Applied Biosystems, Foster City, CA). One micro-
liter of cDNA was added to the PCR reaction mixture
containing 1 XL buffer II, 0.2 mM dNTPs, 0.8 mM
Mg(OAc)2, 0.25 pmol/l of each primer, and 2 u of rTth
DNA polymerase, XL in 100 l. PCR was performed in a
DNA Thermal Cycler 480 (PE Applied Biosystems) at
94°C for 60 s, followed by 30 cycles at 94°C for 30 s and
65°C for 5 min, and finally 1 cycle at 72°C for 10 min. The
PCR product was purified using the QIAquick PCR Puri-
fication Kit (Qiagen, Valencia, CA), digested with the
restriction enzymes SalI and HindIII (Promega), and li-
gated to the pBluescript II SK () vector (which was also
cut by SalI and HindIII) using the Fast-Link DNA Ligation
Kit (Epicentre Technologies, Madison, WI) following the
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manufacturer’s recommendation. The ligation mixture
was used to transform Escherichia coli INVF (Invitro-
gen, Carlsbad, CA). Colonies were picked up, grown in
LB media, and used to prepare plasmid DNA (Sambrook
et al., 1989).
DNA templates for sequencing were purified using the
QIAquick PCR Purification Kit or QIAprep Spin Miniprep
Kit (Qiagen) following the manufacturer’s recommenda-
tions. Sequencing was carried out using the ABI PRISM
Big Dye Terminator Cycle Sequencing Ready Reaction
Kit and the ABI PRISM 377 DNA Sequencer (PE Applied
Biosystems) at the University of Massachusetts Medical
School Nucleic Acid Facility. Primers used for the se-
quencing reaction were 2S (5-AGG GGC CGG AGT ATT
GGG AC-3), 3S (5-CGG CAA GGA TTA CAT CGC CCT
G-3), and 3N (5-CAG GGC GAT GTA ATC CTT GCC
G-3), which cover the coding regions of the 1, 2, and
3 domains of the HLA-B molecule (Ennis et al., 1990).
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